

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGES IN COMPOSITION OF BOARD COMMITTEES

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Kwok Che Chung (“**Mr. Kwok**”) has been appointed as an independent non-executive Director and the chairman of the audit committee of the Company (the “**Audit Committee**”), with effect from May 8, 2026.

Pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), the biographical details of Mr. Kwok are set out below:

Mr. Kwok Che Chung, aged 40, holds a Master of Business Administration from The Hong Kong University of Science and Technology and a Bachelor of Accountancy from Shue Yan University. He is a member of the Hong Kong Institute of Certified Public Accountants and an associate member of The Chartered Institute of Management Accountants. Mr. Kwok has approximately 17 years of professional experience, of which around 10 years were in the auditing profession, including six years at KPMG. He subsequently served as the chief financial officer and joint company secretary of Canggang Railway Limited (stock code: 2169) from 2019 to 2021. He then held senior finance manager positions at CITIC Capital Holdings Limited from 2021 to 2023 and at Qiming Venture Partners from 2023 to 2025. Mr. Kwok currently serves as the financial controller of Arta TechFin Corporation Limited (stock code: 0279) and as the company secretary of CCT Fortis Holdings Limited (stock code: 0138).

Mr. Kwok has entered into a letter of appointment with the Company, pursuant to which his appointment shall take effect from May 8, 2026 for a term of three years, and is subject to retirement and re-election at the forthcoming annual general meeting of the Company. Mr. Kwok is entitled to a remuneration of HKD150,000 per year, which has been recommended by the Remuneration Committee and approved by the Board with reference to (including but not limited to) his duties, responsibilities, performance, current market conditions and the remuneration benchmarks applicable to directors of listed companies of similar size and nature of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Kwok has confirmed that he (i) has no interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (ii) has no relationship with any Directors, senior management or substantial or controlling shareholders of the Company; and (iii) has not held any directorship in listed public companies in Hong Kong or overseas in the last three years preceding the date of his appointment; (iv) does not currently hold any other position with the Company or any of its subsidiaries; and (v) does not have any other information that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, nor is there any other matter that needs to be brought to the attention of the shareholders of the Company.

Mr. Kwok has also confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence as at the date of this announcement.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Ng Ming Kwan (“**Mr. Ng**”) has resigned from his position as independent non-executive Director with effect from May 8, 2026 as he wishes to devote more time to his personal career development. Mr. Ng has also ceased to be the chairman of the Audit Committee with effect from the same day.

The Board would like to take this opportunity to express its warmest welcome to Mr. Kwok on his appointment and its gratitude to Mr. Ng for his long-term support and contribution during his tenure.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, May 8, 2026

As at the date of this announcement, the Board comprises Mr. Ng Tit and Ms. Ng Anna Ching Mei as executive Directors; Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin as non-executive Directors; and Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao and Mr. Kwok Che Chung as independent non-executive Directors.